Abstract
Abstract TMEM92 is a previously uncharacterized gene predicted to encode a 159 amino acid peptide with a single transmembrane domain and sequence homology to the SHISA group of proteins, some of which have a role in early development. In this study we evaluated the expression and function of TMEM92 in prostate cancer. This gene is expressed in primary prostate tumors and the prostate cancer derived cell lines PC3, DU145 and LNCaP, both at the RNA and protein level. TMEM92 expression appears to be cancer specific, as it is not expressed in normal prostate tissue or in normal adult organs. It is also absent from the WPMY-1 cell line, which is derived from normal prostate epithelium. siRNA-mediated knockdown of TMEM92 in PC3 cells induces apoptosis, as does the treatment of these cells with an anti-TMEM92 antibody, whilst neither treatment is cytotoxic for WPMY-1 cells. Taken together these findings suggest that TMEM92 is a potential therapeutic target in prostate cancer. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A193. Citation Format: Richard Morgan, Gui Feng, Hardev S. Pandha. Transmembrane protein TMEM92 as a novel target in prostate cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A193.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call